OCT Angiography-based Monitoring of Neovascular Regression on Fibrovascular Membrane After Preoperative Intravitreal Conbercept Injection

Overview

Journal Graefes Arch Clin Exp Ophthalmol

Specialty Ophthalmology

Date 2019 May 5

PMID 31053944

Citations 11

Authors

Zizhong Hu

Yun Su

Ping Xie

Lu Chen

Jiangdong Ji

Ting Feng

Shaowei Wu

Kang Liang

Qinghuai Liu

Affiliations

Soon will be listed here.

Abstract

Purpose: To quantify the preoperative neovascular change pattern on the fibrovascular membrane (FVM) within 7 days after intravitreal injection of conbercept (IVC) using optical coherence tomography angiography (OCTA) in proliferative diabetic retinopathy (PDR).

Methods: Prospective, observational study of PDR patients with visible FVM receiving or not receiving IVC. Neovascular changes were assessed by OCTA pre-IVC and 1, 3, 5, and 7 days post-IVC. Vessel skeleton density (SD) and vessel density (VD) were quantified by an intensity-based optical microangiography algorithm. The interclass correlation coefficient (ICC) was calculated to assess the agreement between measurements. The SD and VD were compared between follow-ups using repeated-measures analysis in the IVC group.

Results: The ICC was 0.992 (95% confidence interval [CI]: 0.982-0.996) for SD and 0.926 (95% CI: 0.838-0.912) for VD of neovascularization. The neovascularization on FVM significantly regressed in the IVC group (n = 16) compared with no IVC (n = 8) (p = 0.001 for SD and p < 0.001 for VD). The comparisons between consecutive follow-ups showed a statistically significant reduction in SD and VD at 1 and 3 days post-IVC. However, from day 3 onward, the SD and VD remained unchanged. There was no development or progression of tractional retinal detachment within the 7-day period after IVC.

Conclusion: OCTA-based quantification of the neovascularization on FVM in PDR is feasible, with high inter-reader agreement. The regression of neovascularization reaches a plateau 3 days after IVC.

Clinical Trial Registration: This trial is registered with the Chinese Clinical Trial Registry ( http://www.chictr.org.cn , registration number ChiCTR-IPR-17014160).

Citing Articles

Progress in clinical research and applications of retinal vessel quantification technology based on fundus imaging.

Chen N, Zhu Z, Yang W, Wang Q Front Bioeng Biotechnol. 2024; 12:1329263.

PMID: 38456011 PMC: 10917897. DOI: 10.3389/fbioe.2024.1329263.

Effect of Intravitreal Conbercept Injection on Complications of Pars Plana Vitrectomy in Patients with Proliferative Diabetic Retinopathy.

Ding Y, Su N, Luan J, Ni Y, Sun Z J Pers Med. 2023; 13(4).

PMID: 37108958 PMC: 10143612. DOI: 10.3390/jpm13040572.

Optical Coherence Tomography Angiography: Clinical Utility and Future Directions.

Foulsham W, Chien J, Lenis T, Papakostas T J Vitreoretin Dis. 2023; 6(3):229-242.

PMID: 37008547 PMC: 9976135. DOI: 10.1177/24741264221080376.

Effect of intravitreal ranibizumab on fibrovascular membranes in patients with proliferative diabetic retinopathy.

Liang Z, Wang Y, Li J, Yang W, Tu Y, Zhang Y Int J Ophthalmol. 2022; 15(10):1577-1585.

PMID: 36262844 PMC: 9522570. DOI: 10.18240/ijo.2022.10.03.

Downregulation of angiogenic factors in aqueous humor associated with less intraoperative bleeding in PDR patients with NVG receiving conbercept: a randomized controlled trial.

Xu Q, Gong C, Qiao L, Feng R, Liu H, Liu Y BMC Ophthalmol. 2022; 22(1):224.

PMID: 35585570 PMC: 9115965. DOI: 10.1186/s12886-022-02451-6.

References

Avery R, Pearlman J, Pieramici D, Rabena M, Castellarin A, Nasir M . Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006; 113(10):1695.e1-15. DOI: 10.1016/j.ophtha.2006.05.064. View

Arevalo J, Maia M, Flynn Jr H, Saravia M, Avery R, Wu L . Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2007; 92(2):213-6. DOI: 10.1136/bjo.2007.127142. View

Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G . Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol. 2008; 246(6):837-42. DOI: 10.1007/s00417-008-0774-y. View

da R Lucena D, Ribeiro J, Costa R, Barbosa J, Scott I, de Figueiredo-Pontes L . Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). Br J Ophthalmol. 2009; 93(5):688-91. DOI: 10.1136/bjo.2008.151233. View

di Lauro R, De Ruggiero P, di Lauro R, di Lauro M, Romano M . Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010; 248(6):785-91. DOI: 10.1007/s00417-010-1303-3. View

Erdol H, Turk A, Akyol N, Imamoglu H . The results of intravitreal bevacizumab injections for persistent neovascularizations in proliferative diabetic retinopathy after photocoagulation therapy. Retina. 2010; 30(4):570-7. DOI: 10.1097/IAE.0b013e3181bf5ff0. View

Kohno R, Hata Y, Mochizuki Y, Arita R, Kawahara S, Kita T . Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection. Am J Ophthalmol. 2010; 150(2):223-229.e1. DOI: 10.1016/j.ajo.2010.03.016. View

Cheung N, Mitchell P, Wong T . Diabetic retinopathy. Lancet. 2010; 376(9735):124-36. DOI: 10.1016/S0140-6736(09)62124-3. View

Abdelhakim M, Macky T, Mansour K, Mortada H . Bevacizumab (Avastin) as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Ophthalmic Res. 2010; 45(1):23-30. DOI: 10.1159/000314721. View

10.

El-Sabagh H, Abdelghaffar W, Labib A, Mateo C, Hashem T, Al-Tamimi D . Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications. Ophthalmology. 2010; 118(4):636-41. DOI: 10.1016/j.ophtha.2010.08.038. View

11.

Farahvash M, Majidi A, Roohipoor R, Ghassemi F . Preoperative injection of intravitreal bevacizumab in dense diabetic vitreous hemorrhage. Retina. 2011; 31(7):1254-60. DOI: 10.1097/IAE.0b013e31820a68e5. View

12.

Jia Y, Tan O, Tokayer J, Potsaid B, Wang Y, Liu J . Split-spectrum amplitude-decorrelation angiography with optical coherence tomography. Opt Express. 2012; 20(4):4710-25. PMC: 3381646. DOI: 10.1364/OE.20.004710. View

13.

Gupta A, Bansal R, Gupta V, Dogra M . Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single preoperative injection of intravitreal bevacizumab. Int Ophthalmol. 2012; 32(2):135-44. DOI: 10.1007/s10792-012-9541-5. View

14.

Zhang Z, Liu H, Hernandez-Da Mota S, Romano M, Falavarjani K, Ahmadieh H . Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials. Am J Ophthalmol. 2013; 156(1):106-115.e2. DOI: 10.1016/j.ajo.2013.02.008. View

15.

Li X, Xu G, Wang Y, Xu X, Liu X, Tang S . Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology. 2014; 121(9):1740-7. DOI: 10.1016/j.ophtha.2014.03.026. View

16.

Manabe A, Shimada H, Hattori T, Nakashizuka H, Yuzawa M . RANDOMIZED CONTROLLED STUDY OF INTRAVITREAL BEVACIZUMAB 0.16 MG INJECTED ONE DAY BEFORE SURGERY FOR PROLIFERATIVE DIABETIC RETINOPATHY. Retina. 2015; 35(9):1800-7. DOI: 10.1097/IAE.0000000000000577. View

17.

Smith J, Steel D . Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2015; (8):CD008214. PMC: 6599827. DOI: 10.1002/14651858.CD008214.pub3. View

18.

Spaide R, Fujimoto J, Waheed N . IMAGE ARTIFACTS IN OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. Retina. 2015; 35(11):2163-80. PMC: 4712934. DOI: 10.1097/IAE.0000000000000765. View

19.

Su L, Ren X, Wei H, Zhao L, Zhang X, Liu J . INTRAVITREAL CONBERCEPT (KH902) FOR SURGICAL TREATMENT OF SEVERE PROLIFERATIVE DIABETIC RETINOPATHY. Retina. 2015; 36(5):938-43. DOI: 10.1097/IAE.0000000000000900. View

20.

Yang X, Xu J, Wang R, Mei Y, Lei H, Liu J . A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy. J Ophthalmol. 2016; 2016:2473234. PMC: 4808544. DOI: 10.1155/2016/2473234. View